A critical element that distinguishes MacuSight from other companies in the ophthalmic therapeutics space is the company's comprehensive approach to product development. There are three core elements on which the company's development philosophy is focused:

• Highly-Potent, Broad-Acting Small Molecules
• Optimal, Minimally-Invasive, Sustained, Local Drug Administration
• Reapplication of Known Compounds with Proven Safety and Efficacy

The development of therapeutics for the treatment of ocular diseases and conditions has often focused on discovering and advancing an active compound without adequate consideration for drug administration and sustained delivery to target tissues. By placing equal value on the development of broad-acting small molecules and the optimal delivery of those compounds into the eye, MacuSight is working to change the way ocular disease therapeutics are developed. As a result, the company is designing next-generation products for maximum efficacy, safety, convenience and cost-effectiveness.

• Development Approach
• Broad-Acting Compounds
• Proprietary Administration
• Reapplication of Known Compounds

"By placing equal value on the development of compounds and their optimal delivery into the eye, MacuSight is working to change the way ocular disease therapeutics are developed."